StemCell Therapy

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDAs orphan status for remdesivir reserved to encourage the development of rare disease therapies Gilead CEO Daniel ODay had some explaining to do about the companys approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

In addition to trying to reassure patients that they will once again have an avenue to pursue access, ODay also reassured some analysts who had been fretting that Chinas quick comeback from the coronavirus outbreak could derail its ultra-fast schedule for testing the drug in patients. The data are still expected in a few weeks, he says in the letter, putting the readout in April.

ODay emphasizes that Gilead intends to pursue a pricing approach that will make this drug widely available if it proves effective and safe. But no one is quite sure just what the longterm value would be, given the work being done on a variety of vaccines that may be rolled out as early as this fall at least to the most heavily threatened groups.

Unlock this story instantly and join 77,200+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

View post:
David Hallal bags another whopper round, looking to recruit more cell and gene therapy upstarts to ElevateBio BaseCamp - Endpoints News

This entry was posted on April 1, 2020 at 11:49 pm and is filed under Gene therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |